IPSC Logo

Century Therapeutics, Inc. (IPSC) 

NASDAQ
Market Cap
$116.06M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
319 of 776
Rank in Industry
189 of 433

Largest Insider Buys in Sector

IPSC Stock Price History Chart

IPSC Stock Performance

About Century Therapeutics, Inc.

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, …

Insider Activity of Century Therapeutics, Inc.

Over the last 12 months, insiders at Century Therapeutics, Inc. have bought $7,657 and sold $381,816 worth of Century Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Century Therapeutics, Inc. have bought $16M and sold $2.7M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Quimi Daphne (director) — $15,314.

The last purchase of 5,000 shares for transaction amount of $7,657 was made by Quimi Daphne (director) on 2024‑09‑12.

List of Insider Buy and Sell Transactions, Century Therapeutics, Inc.

2024-11-04SaleSVP Finance & Operations
283
0.0003%
$1.23$347+11.65%
2024-11-04SaleChief Operations Officer
1,033
0.0012%
$1.23$1,267+11.65%
2024-09-12Purchasedirector
5,000
0.0059%
$1.53$7,657+0.65%
2024-08-05SaleSVP Finance & Operations
289
0.0003%
$1.83$528-13.98%
2024-08-05SaleChief Operations Officer
1,073
0.0012%
$1.83$1,960-13.98%
2024-07-26SaleSee Remarks
586
0.0007%
$2.50$1,465-35.60%
2024-07-24SaleSee Remarks
1,600
0.002%
$2.52$4,029-5.50%
2024-07-23SaleSee Remarks
200
0.0002%
$2.50$500-4.80%
2024-06-20SaleSee Remarks
5,000
0.0052%
$2.84$14,179-38.48%
2024-06-05SaleSee Remarks
5,000
0.006%
$3.00$14,989-42.79%
2024-05-20SaleSee Remarks
5,000
0.006%
$3.00$14,978-41.28%
2024-05-06SaleSee Remarks
5,000
0.0076%
$3.12$15,619-43.22%
2024-05-03SaleSVP Finance & Operations
257
0.0004%
$3.11$798-39.77%
2024-05-03SaleChief Operations Officer
913
0.0014%
$3.11$2,836-39.77%
2024-04-22SaleSee Remarks
5,000
0.0078%
$3.10$15,490-32.36%
2024-03-07SaleChief Operations Officer
22,831
0.0373%
$5.14$117,342-44.64%
2024-03-06SaleChief Operations Officer
30,684
0.0503%
$4.96$152,340-41.00%
2024-02-16SaleChief Operations Officer
485
0.0008%
$4.86$2,358-36.60%
2024-02-06SaleSVP Finance & Operations
557
0.001%
$4.49$2,499-34.07%
2024-02-06SaleChief Operations Officer
1,784
0.0031%
$4.49$8,005-34.07%

Insider Historical Profitability

<0.0001%
Quimi Daphnedirector
5000
0.0059%
$1.3710
BAYER AKTIENGESELLSCHAFT10 percent owner
12675838
14.9627%
$1.3710<0.0001%
Casdin Elidirector
3206380
3.7849%
$1.3710<0.0001%
Versant Venture Capital VI, L.P.10 percent owner
714095
0.8429%
$1.3710<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Vr Adviser Llc$14.23M4.033.41MNew+$14.23M0.69
Fidelity Investments$14.09M3.993.37M-6.68%-$1.01M<0.01
Casdin Capital$13.4M3.793.21M0%+$00.66
Boxer Capital, LLC$7.32M2.071.75MNew+$7.32M0.15
BlackRock$6.26M1.771.5M-1.37%-$87,006.71<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.